Showing 5461-5470 of 9179 results for "".
- La Fondation La Roche-Posay (North American) Awards 2020 Grant Winnershttps://practicaldermatology.com/news/la-fondation-la-roche-posay-north-american-awards-2020-grant-winners/2460363/And the five La Fondation La Roche-Posay (North America) 2020 research grant winners in the field of dermatology are… Dawn Zhang Eichenfield, MD, PhD, Chief Dermatology Resident at the University of California, San Diego. She received the first place pr
- Label Expansion: Amgen's Otezla Adds Scalp Datahttps://practicaldermatology.com/news/label-expansion-amgens-otezla-adds-scalp-data/2460359/With FDA approval of a supplemental New Drug Application (sNDA), the label for Amgen's Otezla will now be updated to include scalp psoriasis data from the Phase 3 STYLE trial. The label expansion makes Otezla the only oral treatment option to have data specific to moderate
- COVID-19 By the Numbers: April 21 Editionhttps://practicaldermatology.com/news/covid-19-by-the-numbers-april-21-edition/2460357/More than 300,000 Americans could die if all social distancing measures are abandoned, according to documents obtained by the Center for Public Inte
- Can JAK Inhibition Put the Brakes on COVID-19-Associated Cytokine Storm? Incyte Hopes Sohttps://practicaldermatology.com/news/can-jak-inhibition-put-the-brakes-on-covid-19-associated-cytokine-storm-incyte-hopes-so/2460355/Incyte’s JAK inhibitor may play a role in stopping COVID-19-associated cytokine storms. Incyte is starting RUXCOVID, a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of ruxolit
- COVID-19 By the Numbers: April 14 Editionhttps://practicaldermatology.com/news/covid-19-by-the-numbers-april-14-edition/2460346/The US may have already reached its peak for medical resource utilization associated with COVID-19, according to estimates from the Institute for Health Metrics and Evaluation (IHME), an independent population health resea
- Rosacea Awareness Month Brings Focus to Common Skin Diseasehttps://practicaldermatology.com/news/rosacea-awareness-month-brings-focus-to-common-skin-disease/2460342/It’s Rosacea Awareness Month, and the National Rosacea Society (NRS) continues to educate the public on this potentially serious condition estimated to affect more than 16 million Americans. “Although the occurrence of rosacea has been well documented over the centuries, vir
- COVID-19 By the Numbers: April 7 Editionhttps://practicaldermatology.com/news/covid-19-by-the-numbers-april-7-edition/2460341/The peak for medical resource utilization related to COVID-19 in the US is estimated to hit on April 15, and deaths will peak on April 16, according to the Institute for Health Metrics and Evaluation (IHME), an independent population health research center at UW Medicine at the University of
- Dupixent Significantly Improves Severe AD in Childrenhttps://practicaldermatology.com/news/dupixent-significantly-improves-severe-ad-in-children/2460338/Dupixent showed significant improvement in severe atopic dermatitis (AD) for children aged 6 to 11 Years, according to a Phase 3 study. In the trial, Dupixent combined with standard-of-care topical corticosteroids (TCS) significantly improved disease signs, symptoms and health-related q
- Antimalarials for COVID-19: Will Demand Outweigh Supply?https://practicaldermatology.com/news/antimalarials-for-covid-19-will-demand-outweigh-supply/2460337/Chloroquine and hydroxychloroquine may help treat COVID-19, but if mass prophylaxis is advised it's possible that demand will outweigh the supply of antimalarials, say Italian doctors in a letter published online today in the Annals of the Rheumatic Diseases. The results of prelimin
- CSF Live Virtual Meeting to Assess SBA Loans: Tonighthttps://practicaldermatology.com/news/csf-live-virtual-meeting-to-access-sba-loans-tonight/2460334/As dermatology business owners’ heads are swimming trying to figure out the SBA loan to keep afloat during the COVID crisis, CSF, along with George Hruza, MD, immediate past-president of the AAD, and Greg Morganroth, MD, CEO and Founder of California Skin Institute, will discuss the ins-and